Cellectar Biosciences YTD Gain 19.7% and 59.3% EPS Estimate Increase, Q1 Call Scheduled
CLRB•Cellectar Biosciences reported a 19.7% year-to-date return and saw its consensus EPS estimate jump 59.3% over the past three months, earning a Zacks Rank #2. The company will release its Q1 2026 financials and host a May 14 conference call at 8:30 a.m. ET.
1. Year-to-Date Performance
Shares of Cellectar Biosciences have climbed 19.7% year-to-date, outperforming the Medical Products industry loss of 23.2% and the broader sector’s 6.8% decline.
2. Analyst Outlook
Analysts have raised the consensus EPS forecast for CLRB by 59.3% over the past quarter, contributing to a Zacks Rank #2 (Buy) and signaling a stronger earnings outlook.
3. Q1 Results Conference Call
Cellectar will report Q1 2026 results and provide a corporate update on May 14, 2026 at 8:30 a.m. Eastern Time via webcast and conference call (Webcast ID: 63374), with a replay available on the company’s investor relations site.
4. Clinical Pipeline Overview
The company’s late-stage pipeline includes iopofosine I-131 in Phase 2b trials for Waldenström Macroglobulinemia and multiple myeloma, alongside Phase 1b studies of CLR-125 in solid tumors, benefiting from multiple Orphan Drug, Breakthrough Therapy and PRIME designations.
